Iovance (IOVA) stock jumps again in premarket after 31% surge on earnings, sarcoma data
Iovance Biotherapeutics shares rose about 4% premarket Wednesday after a 30.8% jump Tuesday. The company reported $87 million in fourth-quarter product revenue, a 50% gross margin, and a $71.9 million net loss. Citizens upgraded the stock to Market Outperform with a $5 target. Iovance plans to issue 2026 revenue guidance soon.